StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.95−0.10 (-9.87%)

Close on Nov 16, 2026Market cap $26.27MP/E –Yield –

Inmune Bio enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Inmune Bio's enterprise value was $12.01M on Nov 11, 2026, against $18.52M a year earlier. Over the last 5 years it ranged from $5.29M to $194.21M, with a median of $82.92M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$12.01M-12.6%
2025Dec 31, 2025$13.74M-81.0%
2024Dec 31, 2024$72.49M-54.9%
2023Dec 29, 2023$160.69M+182.0%
2022Dec 30, 2022$56.98M-41.6%
2021Dec 31, 2021$97.53M-52.9%
2020Dec 31, 2020$207.26M+276.6%
2019Dec 31, 2019$55.04M–

More Inmune Bio figures

See a number that looks wrong?